| Literature DB >> 29541362 |
Sreedhar R Tummalapalli1, Rohit Bhat1, Agnieszka Chojnowski1, Monika Prorok1, Tamara Kreiss1, Ronald Goldberg1, Stacie Canan2, Natalie Hawryluk2, Deborah Mortensen2, Vikram Khetani3, Jerome Zeldis3, John J Siekierka1, David P Rotella1.
Abstract
Lymphatic filariasis infects over 120 million people worldwide and can lead to significant disfigurement and disease. Resistance is emerging with current treatments, and these therapies have dose limiting adverse events; consequently new targets are needed. One approach to achieve this goal is inhibition of parasitic protein kinases involved in circumventing host defense mechanisms. This report describes structure-activity relationships leading to the identification of a potent, orally bioavailable stress activated protein kinase inhibitor that may be used to investigate this hypothesis.Entities:
Year: 2018 PMID: 29541362 PMCID: PMC5846038 DOI: 10.1021/acsmedchemlett.7b00477
Source DB: PubMed Journal: ACS Med Chem Lett ISSN: 1948-5875 Impact factor: 4.345